首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1535701

多形性胶质母细胞瘤治疗市场- 按治疗（手术、放射、标靶、化疗、免疫疗法）、药物类别（替莫唑胺、贝伐单抗、洛莫司汀）、剂型（口服、肠胃外）、性别、最终用途- 全球预测（2024 - 2032）

Glioblastoma Multiforme Treatment Market - By Treatment (Surgery, Radiation, Targeted, Chemotherapy, Immunotherapy), Drug Class (Temozolomide, Bevacizumab, Lomustine), Dosage Form (Oral, Parenteral), Gender, End-use - Global Forecast (2024 - 2032)

出版日期: 2024年06月13日 | 出版商:

Global Market Insights Inc. | 英文 215 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于研究机构之间的合作关係不断增加以及医学研究的进步，2024年至2032年全球多形性胶质母细胞瘤治疗市场规模将创下8.6%的复合年增长率。

持续的合作努力正在导致创新疗法的开发并改进现有疗法，以应对侵袭性脑肿瘤的挑战。研究人员也共同努力，整合资源和专业知识，从而找到更有效的胶质母细胞瘤治疗方法。例如，2023 年2 月，argTex 与IAG 合作，应用人工智慧评估一种新型临床候选药物对多形性胶质母细胞瘤患者的效果，以加强治疗评估并推进针对具有挑战性的脑肿瘤的治疗选择。

市场分为治疗、药物类别、剂型、性别、最终用途和地区。

在治疗方面，到 2032 年，多形性胶质母细胞瘤治疗行业的化疗部分将经历显着的增长。正在进行的研究正在帮助优化化疗方案，以提高疗效并最大限度地减少副作用。越来越多的努力致力于开发更有针对性的药物，并将化疗与放射和免疫疗法等其他治疗方法相结合，以实现更好的患者治疗效果并延长存活率。

按性别划分，预计2024 年至2032 年，女性多形性胶质母细胞瘤治疗市场价值将上升，原因是满足女性患者特定需求的需求不断增加，同时考虑到疾病进展和治疗反应中的性别差异。正在进行的研究重点是胶质母细胞瘤如何独特地影响女性，并相应地调整治疗方法。此外，治疗计划与标靶治疗和个人化方法相结合，以改善女性患者的治疗结果。

从区域来看，在癌症研究资金增加以及政府和监管措施支持的推动下，欧洲多形性胶质母细胞瘤治疗产业规模预计将在 2024 年至 2032 年间强劲成长。研究团队正在利用额外的资金来探索新的治疗方法并增强现有的疗法。各国政府和监管机构正在提供资源和简化流程，以加速创新疗法的发展。支持措施的综合影响将改变整个欧洲治疗这种侵袭性脑肿瘤的方法。

产业生态系统分析
产业影响力
- 成长动力
  - 胶质母细胞瘤的发生率增加
  - 提高疾病意识和早期诊断
  - 研发活动数量增加
- 产业陷阱与挑战
  - 即使治疗后胶质母细胞瘤的復发率也很高
  - 治疗费用高
成长潜力分析
监管环境
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按处理方式，2021 - 2032 年

主要趋势
手术
放射治疗
化疗
标靶治疗
肿瘤治疗现场治疗
免疫疗法

第 6 章：市场估计与预测：按药物类别，2021 - 2032 年

主要趋势
替莫唑胺
贝伐珠单抗
洛莫司汀
卡莫司汀晶圆

第 7 章：市场估计与预测：按剂型，2021 - 2032

主要趋势
口服
注射用

第 8 章：市场估计与预测：按性别划分，2021 - 2032 年

主要趋势
男性
女性

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
癌症治疗中心
门诊手术中心
其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

Amgen Inc.
Amneal Pharmaceuticals
Curtana Pharmaceuticals
Denovo Biopharma
Eisai Co. Ltd. (Gliadel)
F. Hoffmann La Roche Ltd (Genetech USA)
Karyopharm Therapeutics
Merck & Co. Inc.
Novocure GmbH
Pfizer, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries

简介目录

Product Code: 9866

Global Glioblastoma Multiforme Treatment Market size will record 8.6% CAGR from 2024 to 2032, due to increasing partnerships among research institutions along with advancements in medical research.

The ongoing collaborative efforts are leading to the development of innovative therapies and improving existing treatments to address the challenges of the aggressive brain tumor. Researchers are also working together to combine resources and expertise, leading to more effective approaches in managing glioblastoma. For instance, in February 2023, argTex partnered with IAG to apply AI in evaluating the effects of a novel clinical candidate for glioblastoma multiforme patients to enhance treatment assessment and advance therapeutic options for the challenging brain tumor.

The market is segregated into treatment, drug class, dosage form, gender, end-use, and region.

In terms of treatment, the chemotherapy segment in the glioblastoma multiforme treatment industry is set to experience growth at a significant rate through 2032. This is due to the rising prominence of chemotherapy in targeting the dividing cancer cells to slow the tumor growth. Ongoing research is helping in optimizing chemotherapy regimens to enhance effectiveness and minimize side effects. Increasing efforts are directed towards developing more targeted drugs and combining chemotherapy with other treatments like radiation and immunotherapy to achieve better patient outcomes and extend survival rates.

By gender, the glioblastoma multiforme treatment market value from the female segment is projected to rise from 2024 to 2032, fueled by the increasing need to address the specific needs of female patients while considering gender differences in disease progression and treatment response. Ongoing research is focusing on how glioblastoma affects women uniquely and tailoring therapies accordingly. Moreover, treatment plans are integrated with targeted therapies and personalized approaches to improve outcomes for female patients.

Regionally, the Europe glioblastoma multiforme treatment industry size is projected to depict robust growth between 2024 and 2032, driven by increasing funding for cancer research along with supportive government and regulatory initiatives. Research teams are utilizing additional funding to explore new treatment approaches and enhance existing therapies. Governments and regulatory bodies are providing resources and streamlined processes to accelerate the development of innovative treatments. The combined impacts of the supportive measures will transform the approach to treating this aggressive brain tumor across Europe.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of glioblastoma
  - 3.2.1.2 Rising awareness and early diagnosis of disease
  - 3.2.1.3 Increase in the number of R&D activities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High recurrence rate of glioblastoma even after treatment
  - 3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Surgery
5.3 Radiation therapy
5.4 Chemotherapy
5.5 Targeted therapy
5.6 Tumor treating field therapy
5.7 Immunotherapy

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Temozolomide
6.3 Bevacizumab
6.4 Lomustine
6.5 Carmustine wafers

Chapter 7 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Male
8.3 Female

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 Hospitals
9.3 Cancer treatment centers
9.4 Ambulatory surgical centers
9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa